Literature DB >> 24453746

Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Amy Perrin Ross1, June Halper1, Colleen J Harris1.   

Abstract

There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unaddressed patient concerns, unnoticed or underrecognized side effects of therapies (both disease modifying and symptomatic), and suboptimal therapeutic response. Systematic evaluation of specific symptoms and potential side effects can minimize the likelihood of overlooking important information. However, given the number of potential symptoms and adverse events that patients may experience, an exhaustive evaluation can be time-consuming. Clinicians are thus challenged to balance thoroughness with brevity. A need exists for a brief but comprehensive objective assessment tool that can be used in practice to 1) help clinicians assess patients when they present with symptoms of a relapse, and 2) evaluate outcomes of acute management. A working group of expert nurses convened to discuss recognition and management of relapses. In this article, we review data related to recognition and management of relapses, discuss practical challenges, and describe the development of an assessment questionnaire that evaluates relapse symptoms, the impact of symptoms on the patient, and the effectiveness and tolerability of acute treatment. The questionnaire is designed to be appropriate for use in MS specialty clinics, general neurology practices, or other practice settings and can be administered by nurses, physicians, other clinicians, or patients (self-evaluation). The relapse assessment questionnaire is currently being piloted in a number of practice settings.

Entities:  

Year:  2012        PMID: 24453746      PMCID: PMC3882990          DOI: 10.7224/1537-2073-14.3.148

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  79 in total

1.  EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses.

Authors:  F Sellebjerg; D Barnes; G Filippini; R Midgard; X Montalban; P Rieckmann; K Selmaj; L H Visser; P S Sørensen
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

Review 2.  Relapse management in multiple sclerosis.

Authors:  Ben W Thrower
Journal:  Neurologist       Date:  2009-01       Impact factor: 1.398

3.  Intravenous methylprednisolone for multiple sclerosis in relapse.

Authors:  M P Barnes; D E Bateman; P G Cleland; D J Dick; T J Walls; P K Newman; M Saunders; P J Tilley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

4.  Melanocortin 4 receptor activation induces brain-derived neurotrophic factor expression in rat astrocytes through cyclic AMP-protein kinase A pathway.

Authors:  Carla Caruso; Lila Carniglia; Daniela Durand; Patricia V Gonzalez; Teresa N Scimonelli; Mercedes Lasaga
Journal:  Mol Cell Endocrinol       Date:  2011-07-22       Impact factor: 4.102

Review 5.  Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications.

Authors:  Christine Stadelmann
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

6.  Beneficial plasma exchange response in central nervous system inflammatory demyelination.

Authors:  Setty M Magaña; B Mark Keegan; Brian G Weinshenker; Bradley J Erickson; Sean J Pittock; Vanda A Lennon; Moses Rodriguez; Kristine Thomsen; Stephen Weigand; Jay Mandrekar; Linda Linbo; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2011-03-14

Review 7.  Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

Authors:  G Filippini; F Brusaferri; W A Sibley; A Citterio; G Ciucci; R Midgard; L Candelise
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

9.  High dose oral steroids commonly used to treat relapses in Canadian MS clinics.

Authors:  S A Morrow; L M Metz; M Kremenchutzky
Journal:  Can J Neurol Sci       Date:  2009-03       Impact factor: 2.104

Review 10.  MRI relapses have significant pathologic and clinical implications in multiple sclerosis.

Authors:  Anthony Traboulsee
Journal:  J Neurol Sci       Date:  2007-03-07       Impact factor: 3.181

View more
  7 in total

1.  Assessment and Treatment Strategies for a Multiple Sclerosis Relapse.

Authors:  Cynthia Wang; America Ruiz; Yang Mao-Draayer
Journal:  J Immunol Clin Res       Date:  2016-12-07

2.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

3.  The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Authors:  Helen Beckmann; Christoph Heesen; Matthias Augustin; Christine Blome
Journal:  Int J MS Care       Date:  2021-12-07

Review 4.  Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Katja Thomas
Journal:  BMC Neurol       Date:  2016-08-02       Impact factor: 2.474

Review 5.  Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.

Authors:  Elizabeth A Mills; Ali Mirza; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2017-03-29       Impact factor: 4.003

6.  Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.

Authors:  Amy Perrin Ross; Alona Williamson; Jennifer Smrtka; Tracy Flemming Tracy; Carol Saunders; Constance Easterling; John Niewoehner; Nicole Mutschler
Journal:  Mult Scler Int       Date:  2013-05-26

7.  REFRESH protocol: a non-inferiority randomised clinical trial comparing internet and teleconference to in-person 'Managing Fatigue' interventions on the impact of fatigue among persons with multiple sclerosis.

Authors:  Matthew Plow; Tanya Packer; Virgil G Mathiowetz; Kathy Preissner; Setareh Ghahari; Abdus Sattar; Francois Bethoux; Marcia Finlayson
Journal:  BMJ Open       Date:  2020-08-16       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.